CoChat

IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells

Open access
Parihar, Robin, Dierksheide, Julie, Hu, Yan, Carson, William E. · 2002 · Journal of Clinical Investigation

The DOI matches its Crossref record; 40 of the 50 references it cites were found in a registry or an index.

Abstract

The anti-tumor activity of recombinant mAb's directed against tumor cell growth receptors has generally been considered to result from direct antiproliferative effects, the induction of apoptosis, or possibly Ab-dependent cellular cytotoxicity mediated against tumor targets.However, it remains unclear to what degree these mechanisms actually aid in the clearance of Ab-coated tumor cells in vivo.We show here that NK cells secrete a distinct profile of potent immunostimulatory cytokines in response to dual stimulation with Ab-coated tumor cells and IL-12.This response could not be duplicated by costimulation with other ILs and was significantly enhanced in the presence of monocytes.Cytokine production was dependent upon synergistic signals mediated by the activating receptor for the Fc portion of IgG (FcγRIII) and the IL-12 receptor expressed on NK cells.Coadministration of Ab-coated tumor cells and IL-12 to BALB/c mice resulted in enhanced circulating levels of NK cell-derived cytokines with the capacity to augment anti-tumor immunity.These findings suggest that, in addition to mediating cellular cytotoxicity and apoptosis, the anti-tumor activity of mAb's might also result from activation of a potent cytokine secretion program within immune effectors capable of recognizing mAb-coated targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci0215950

Cites

40 of 50 references verified0 citation errors · 10 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 10

  1. Sarup, J.C., et al. 1991. Characterization of an anti-p185HER2 mono- clonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. 1:72-82.
  2. Baselga, J., and Albanell, J. 2001. Mechanisms of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12:S35-S41. · doi:10.1023/a:1011163824080
  3. Sliwkowski, M.X., et al. 1999. Nonclinical studies addressing the mech- anism of action of trastuzumab (Herceptin). Semin. Oncol. 26:60-70.
  4. Penichet, M.L., et al. 1999. In vivo properties of three human HER2/neu- expressing murine cell lines in immunocompetent mice. Lab. Anim. Sci. 49:179-188.
  5. Fleming, G.F., et al. 1999. A phase I CALGB trial of recombinant human anti-HER2 monoclonal antibody plus low-dose interleukin2 in solid tumors. Proc. Am. Soc. Clin. Oncol. 18:184a. (Abstr. 710)
  6. Weiner, L.M., et al. 1995. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. 55:4586-4593.
  7. Penichet, M.L., Dela Cruz, J.S., Shin, S.U., and Morrison, S.L. 2001. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum. Antibodies. 10:43-49. · doi:10.3233/hab-2000-10107
  8. Peng, L.S., Penichet, M.L., and Morrison, S.L. 1999. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J. Immunol. 163:250-258. · doi:10.4049/jimmunol.163.1.250
  9. Cavallo, F., et al. 1999. Immune events associated with the cure of estab- lished tumors and spontaneous metastases by local and systemic inter- leukin-12. Cancer Res. 59:414-421.
  10. Parihar, R. et al. 2001. A phase I trial of Herceptin and interleukin-12 in patients with HER2-overexpressing malignancies. Proc. Am. Soc. Clin. Oncol. 20:258a. (Abstr. 1031)

Cited by

Items 201–212 of 212

Metadata

Authors
Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E.
Affiliations
  • The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
  • The Ohio State University (US)
Corresponding author
Carson, William E.
Venue
Journal of Clinical Investigation
Published
2002-10-01
Volume
110
Issue
7
Pages
983-992
ISSN
0021-9738 (ISSN-L)
OpenAlex
W4237052860
Cited by
23
References
40
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 1 · 2020: 2 · 2019: 2 · 2018: 2 · 2015: 2 · 2014: 1 · 2013: 1
FWCI
0.11
Type
journal article
Language
en
Open access
Locations
Journal of Clinical Investigation (publishedVersion)
Funders
  • Ohio State University
  • National Institutes of Health
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
IL-12, natural killer cells, monoclonal antibodies, antitumor immunity, FcγRIII, IL-12 receptor, monocytes, antibody-dependent cellular cytotoxicity, anti-idiotypic antibodies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.